IL13RA2 and glioblastoma: Currently, there are several CAR-T trials targeting GBM tumors (see Table 1) expressing EGFRvIII, IL13Rα2, HER2, B7-H3, Chlorotoxin, CD133, EphA2, IL7R1, NKG2D, CD70, IL8, and GD2 in newly diagnosed, advanced-stage, and recurrent tumors [45,46,47,48,49,50,51].